Clinical manifestation of neuroendocrine tumor – carcinoid heart disease
F. R. Akildzhonov,
Yu. I. Buziashvili,
E. U. Asymbekova,
E. V. Artamonova,
E. F. Tugeeva,
D. R. Akhmedov,
A. V. Basanets https://doi.org/10.33667/2078-5631-2023-17-38-41
Abstract
Carcinoid heart disease (CHD) is a rare manifestation of the carcinoid syndrome, but eventually occurs in most patients and is a major cause of cardiovascular mortality. The development of CHD is known to be a negative prognostic factor in patients with advanced neuroendocrine tumors. The mechanism of CHD pathophysiology remains poorly understood. Progress in early diagnosis and improvement of therapeutic approaches over the last decade has reduced hospital mortality in this cohort of patients. In this clinical case we summarize clinical features of the examination, treatment of and demonstrate modern pathogenetic aspects of the development of this condition.
About the Authors
F. R. Akildzhonov
National Medical Research Center for Cardiovascular Surgery n. a. A. N. Bakulev
Russian Federation
Russian Federation
Akildzhonov Firdavsdzhon R., postgraduate of Clinico-Diagnostic Dept
Moscow
Yu. I. Buziashvili
National Medical Research Center for Cardiovascular Surgery n. a. A. N. Bakulev
Russian Federation
Russian Federation
Buziashvili Yuri I., DM Sci (habil.), professor, academician of RAS, head of Clinico-Diagnostic Dept
Moscow
E. U. Asymbekova
National Medical Research Center for Cardiovascular Surgery n. a. A. N. Bakulev
Russian Federation
Russian Federation
Asymbekova El’mira U., DM Sci (habil.), leading researcher of Clinico-Diagnostic Dept
Moscow
E. V. Artamonova
National Medical Research Centre of Oncology n. a. N. N. Blokhin; Russian National Research Medical University n. a. N. I. Pirogov; Moscow Regional Research Clinical Institute n. a. M. F. Vladimirsky
Russian Federation
Russian Federation
Artamonova Elena V., DM Sci (habil.), head of Dept of Antitumor Drug Therapy No. 1, Dept of Drug Treatment; professor at Dept of Oncology and Radiation Therapy; head of Dept of Oncology and Thoracic Surgery
Moscow
E. F. Tugeeva
National Medical Research Center for Cardiovascular Surgery n. a. A. N. Bakulev
Russian Federation
Russian Federation
Tugeeva Elvina F., DM Sci (habil.), senior researcher of Clinico-Diagnostic Dept
Moscow
D. R. Akhmedov
National Medical Research Center for Cardiovascular Surgery n. a. A. N. Bakulev
Russian Federation
Russian Federation
Akhmedov Daniyal R., resident of Clinico-Diagnostic Dept
Moscow
A. V. Basanets
National Medical Research Center for Cardiovascular Surgery n. a. A. N. Bakulev
Russian Federation
Russian Federation
Basanets Anna V., resident of Clinico-Diagnostic Dept
Moscow
References
1. Klöppel G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med. 2017; 33 (5): 324–330. DOI: 10.1159/000481390.
2. Bhattacharyya S., Davar J., Dreyfus G., Caplin M. Carcinoid heart disease. Circulation. 2007; 116 (24): 2860–2865. DOI: 10.1161/circulationaha.107.701367.
3. Ghukasyan H. Hedinger Syndrome: A Rare Cardiac Manifestation of Carcinoid Syndrome. Cureus. 2022; 14 (7): e26528. DOI: 10.7759/cureus.26528.
4. Gomes-Porras M., Cárdenas-Salas J., Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: A Review. Int J Mol Sci. 2020; 21 (5): 1682. DOI: 10.3390/ijms21051682.
5. Baron E., Szymanski C., Hergault H. Progression of Carcinoid Heart Disease in the Modern Management Era. J Am Heart Assoc. 2021; 10 (23): e020475. DOI: 10.1161/jaha.120.020475.
6. Jin C., Sharma A., Thevakumar B. Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management. Cardiology. 2021; 146 (1): 65–73. DOI: 10.1159/000507847.
7. Driesbaugh K., Branchetti E., Grau J. Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation. J Mol Cell Cardiol. 2018; 115: 94–103. DOI: 10.1016/j.yjmcc.2017.12.014.
8. Levy S., Kilgallen A., Korse C. Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study. Cancers (Basel). 2022; 14 (10): 2361. DOI: 10.3390/cancers14102361.
9. Buchanan-Hughes A., Pashley A., Feuilly M., Marteau F., Pritchard D., Singh S. Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review. Neuroendocrinology. 2021; 111 (1–2): 1–15. DOI: 10.1159/000506744.
10. Bober B., Saracyn M., Kołodziej M. Carcinoid Heart Disease: How to Diagnose and Treat in 2020. Clin Med Insights Cardiol. 2020; 14: 1179546820968101. DOI: 10.1177/1179546820968101.
11. Nguyen A., Schaff H., Abel M. Improving outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg. 2019; 158 (1): 99–107.e2. DOI: 10.1016/j.jtcvs.2018.09.025.
Review
For citations:
Akildzhonov F.R., Buziashvili Yu.I., Asymbekova E.U., Artamonova E.V., Tugeeva E.F., Akhmedov D.R., Basanets A.V. Clinical manifestation of neuroendocrine tumor – carcinoid heart disease. Medical alphabet. 2023;(17):38-41. (In Russ.) https://doi.org/10.33667/2078-5631-2023-17-38-41
Views:
285
Email this article 